Dublin medtech OncoMark raises €2.1m in funding

Firm ends to prevent ineffective treatment for early stage breast cancer

19th February, 2017
Dawn Walsh, Kernel Capital; Des O’Leary, chief executive, OncoMark; Professor William Gallagher, director, UCD Conway Institute and co-founder, OncoMark; Deirdre Glenn, manager, Lifesciences Sector, Enterprise Ireland, and Kevin Healy, senior manager, Corporate Banking Ireland, Bank of Ireland

Company: Oncomark

Done deal:€2.1m investment

The clincher:“OncoMark aims to prevent early stage breast cancer patients’ exposure to ineffective treatment and needless toxicity” - Orla Rimmington, partner, Kernel Capital

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Tom Maguire: Tax changes we make now could help business for years

More Business Tom Maguire 9 months ago

The Daily Briefing

The Daily Briefing